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The increased risk of cardiovascular events in older men is multifactorial, but the significant reduction 
of testosterone levels has been involved. As this hormone regulates the expression of TFPI by unknown 
mechanisms, we aimed to evaluate the role of miRNAs in the regulation of TFPIα expression under 
normal conditions and in response to androgens. In silico studies allowed the selection of 4 miRNAs 
as potential TFPIα regulators. Only miR-27a/b-3p significantly reduced TFPIα expression in two 
endothelial cell lines. Luciferase assays demonstrated a direct interaction between miR-27a/b-3p and 
TFPI 3′UTR. Ex vivo analysis of TFPI and miRNA levels in 74 HUVEC samples from healthy subjects, 
showed a significant and inverse correlation between TFPI and miR-27a-3p. Moreover, anticoagulant 
activity of TFPIα from cells supernatants decreased ~30% with miR-27a/b-3p and increased 
~50% with anti-miR-27a/b-3p. Interestingly, treatment of EA.hy926 with a physiological dose of 
dihydrotestosterone (30 nM) significantly increased (~40%) TFPIα expression with a parallel decreased 
(~50%) of miR-27a/b-3p expression. In concordance, increased levels of miR-27a/b-3p normalized the 
up-regulation induced by testosterone. Our results suggest that testosterone is a hinge in miR-27/TFPIα 
regulation axis. Future studies are needed to investigate whether testosterone variations are involved 
in a miR-27/TFPIα dysregulation that could increase the cardiovascular risk.
Tissue factor pathway inhibitor (TFPI), the natural and primary inhibitor of tissue factor (TF), is a prime candi-
date to control thrombosis through the regulation of TF1. Few studies have investigated the mechanisms impli-
cated in TFPI regulation which may be of paramount importance to better define its biology and its role in 
thrombosis. The variability of TFPI plasma levels due to genetic factors account for almost 50%2–5, but little is 
known on other factors, in particular hormones.
During the last years, different groups including ours, have evaluated the role of miRNAs in the regulation 
of haemostasis6, as this regulation may have an impact on the thrombotic aetiology7. MicroRNAs (miRNAs), 
are small non-coding RNAs that regulate protein expression that have been involved in the regulation of many 
complex biological mechanisms8 and in many pathological conditions9,10. Thus, three evidences encourage a deep 
characterization of the testosterone-miRNA-TFPI triad as a new regulatory axis in endothelial function: (i) exper-
imental studies have shown that testosterone up-regulates TFPI expression in endothelial cells11,12; (ii) low levels 
of testosterone are associated with low plasma levels of TFPI and an increase of cardiovascular risk13–15, and (iii) 
testosterone induces changes in miRNA expression pattern in prostate cancer cells16,17 or muscle18,19.
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Therefore, the purpose of this study was to determine whether TFPIα is regulated by miRNAs through a 
testosterone-dependent mechanism.
Results and Discussion
miR-27a/b-3p directly bind and regulate the expression of TFPIα. We first sought to identify miR-
NAs as novel and specific regulatory elements in TFPI 3′ UTR. Computational results from the different algo-
rithms showed up 4 miRNA candidates: miR-27a/b-3p, miR-19b and miR-24 (Table 1).
We validated in silico results by transfecting EA.hy926 endothelial cells (ECs) with all the miRNA candidates. 
Only miR-27a/b-3p mimics produced a decrease in both TFPI mRNA and extracellular TFPIα levels (Fig. 1A and B), 
as well as anti-miR-27a/b-3p produced an increase in TFPI mRNA and extracellular TFPIα levels (Fig. 1C and D). 
These results were confirmed in another EC type (Fig. 1E–H). To reveal whether the effect of miR-27a/b-3p on 
TFPIα was direct or indirect, we cloned a fragment of TFPI 3′ UTR (NM_006287) into a luciferase vector. As a 
negative control, we deleted the seed region for miR-27a/b-3p. MiR-27a/b-3p significantly reduced the luciferase 
activity, whereas no effect was observed with the mutated luciferase vector (Fig. 2). Thus, we here described for 
the first time that TFPIα is directly regulated by two miRNAs, miR-27a/b-3p in ECs and this post-transcriptional 
regulation of TFPIα might have consequences on the endothelial functions. Emerging evidences have already 
pointed toward miRNAs as relevant regulators of haemostatic proteins. For example, TF is regulated by miRNAs 
from the miR-17~92 cluster in monocytes7 and by miR-223 in ECs20. On the other hand, protein S (PS), a cofactor 
for full length TFPIα 21, is regulated by miR-49422. Thus, we can speculate that the regulation of TFPIα , TF, and 
PS may be exerted by a miRNA hub that modulate the TF/TFPI axis, as it has been described for other signaling 
pathways20,23. Indeed, in silico analyses showed that miR-27a/b-3p could also target TF and PS, although these 
interactions have to be further demonstrated in vitro.
miR-27a-3p inversely correlated with TFPI expression in HUVECs. With the aim to test whether the 
TFPI:miR-27a/b-3p interaction has physiological consequences, we quantified these transcripts in 74 HUVEC 
samples (from healthy human donors). By using a correlation model, we found that TFPI mRNA and miR-27a-3p 
levels were inversely and significantly associated (Fig. 3A). However, we found a lack of agreement between the 
in vitro and ex vivo results for miR-27b-3p (Fig. 3B) that may be justified because its expression was 18-fold lower 
than miR-27a-3p in HUVECs (Fig. 3C), which is in accordance with published results24. Indeed, miR-27a and 
miR-27b were not correlated (Fig. 3D). Therefore it is expected that, in physiological conditions, the lower con-
centration of miR-27b-3p in HUVECs may explain its lack of association with TFPI levels and potentially a minor 
role in regulating TFPIα in ECs. As a control, we evaluated the correlations of miR-19b and miR-24 with TFPI. 
As expected, no significant correlations were observed (Fig. 3E and F), which strengthen the results obtained 
for miR-27a-3p. Accordingly, the quantification of miR-27a/b-3p might be of interest in pathological conditions 
where miRNA deficiency or over-expression may have an important impact25.
miR-27a/b-3p levels modulate the anticoagulant effect of TFPIα. We next investigated the func-
tional relevance of TFPIα regulation by miR-27a/b-3p. TFPIα anticoagulant activity was measured in the super-
natant of HUVECs transfected with both miRNAs. Transfection with miR-27a/b-3p significantly decreased 
TFPIα anticoagulant activity, while anti-miR-27a/b-3p significantly increased TFPIα anticoagulant activ-
ity (Fig. 4). These latter observations were further confirmed in EA.hy926 cells transfected with miR-27a-3p 
(Figure S1). This finding suggests that miR-27a/b-3p levels variations may have an impact on TFPIα functionality. 
Hypoxic conditions have been described previously to up-regulate miR-27a/b-3p expression26 while infective and 
inflammatory processes down-regulate their expression27,28. Given the extensive cross-talk between the coagu-
lation and inflammatory systems, TFPI included29, additional studies are certainly needed to reveal the role of 
miR-27a/b-3p in TFPIα regulation and the impact on their activity under pathological conditions.
TFPIα regulation by testosterone is dependent of miRNA expresssion. It is described that testos-
terone increases TFPI mRNA and protein levels11,12. Nevertheless, the specific mechanisms of this regulation are 
largely unknown. In addition, testosterone may also regulate miRNA expression16,19. Thus, we wondered whether 
miR-27a/b-3p could be implicated in TFPI regulation by testosterone. We treated EA.hy926 cells with a physio-
logical dose of the main testosterone metabolite, dihydrotestosterone (DHT, 30 nM) and we observed a significant 
increase of both TFPI mRNA (Fig. 5A) and protein after 24 h (Fig. 5B). Indeed, such doses of DHT decreased 
miR-27a/b-3p (Fig. 5C and D). These results were also shown in HUVECs (Figure S2). Key enzymes implicated 






DIANAmt miRDB PITA RNA22 PICTAR5
Position 2546-2553 of TFPI 
3′ UTR hsa-miR-27a-3p 
5′ … AAUUAAGUGCAUCUAACUGUGAA… 
||||||| 3′ CGCCUUGAAUCGGUGACACUU − 0.36 − 0.99 + + − − + 
Position 2546-2553 of TFPI 
3′ UTR hsa-miR-27b-3p 
5′ … AAUUAAGUGCAUCUAACUGUGAA… 
||||||| 3′ CGUCUUGAAUCGGUGACACUU − 0.36 − 0.99 + + − − + 
Position 865-872 of TFPI 3′ 
UTR hsa-miR-19 
5′ … CAGUUAUCAUUAGGAUUUGCACA… 
||||||| 3′ AGUCAAAACGUACCUAAACGUGU − 0.15 − 0.63 + + + − − 
Position 1040-1047 of TFPI 
3′ UTR hsa-miR-24 
5′ … AUCUUUCAUUUAUUGCUGAGCCA… 
||||||| 3′ GACAAGGACGACUUGACUCGGU − 0.15 − 0.53 + + − − + 
Table 1.  In silico search of potential miRNAs able to bind to 3′ UTR of TFPI.
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Figure 1. miR-27a/b-3p directly inhibit the expression of TFPIα. Endothelial cells were transfected with 
different miRNA precursors (100 nM) selected by in silico prediction or a scrambled control and mRNA levels 
were measured after 48 h by qRT-PCR in EA.hy926 (A) and in HUVECs (E). Protein levels in cell culture 
supernatants were measured by densitometry after western blotting with specific anti-TFPI antibody in 
EA.hy926 (B) and in HUVECs (F). A representative blot is shown. The TFPI mRNA in EA.hy926 (C) and in 
HUVECs (G) and the respective protein levels (D,F) of cells transfected with miR-27a/b-3p inhibitors, and 
determined by the same methods and in the same conditions, is also shown. The 2−ΔCt method was followed to 
calculate the relative abundance of mRNA compared with endogenous control expression of β -actin (ACTB) 
(Ct = Threshold Cycle; Δ Ct = Ct sample gene - Ct endogenous control). For miR-27b and miR-24 the same 
scrambled control was used. Representative blots are shown. All results are represented as mean ± SD from at 
least three experiments performed in triplicate (*p < 0.05; **p < 0.01; ***p < 0.001).
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in the miRNA biogenesis: Drosha, Ago2, Exportin 5, and Dicer were not significantly affected by DHT treat-
ment (Fig. 5E). Therefore, regulation of miR27a/b-3p by testosterone seems to be specific and non-dependent of 
miRNA biogenesis machinery. Although it has been shown that testosterone increases the rate of pri-miR-27a 
maturation through the binding of the androgen receptor (AR) to the promoter of the gene in LNCaP prostate 
cancer cells30, our results showed that DHT provokes a decrease of miR-27a/b-3p in ECs. These results could be 
partially explained through differences of regulation pathways between both cell types that can certainly have an 
impact on the miR-27a/b-3p-testosterone regulation31. Future studies are needed to investigate whether testoster-
one variations are involved in a miR-27/TFPIα dysregulation that could increase the cardiovascular risk inherent 
to aging. However, an important limitation of forthcoming studies will be the accessibility to the adequate sam-
ples, e.g. ECs, that can be circumvented by the use of an appropriate animal model.
Finally, combination of androgen treatment with miR-27a/b-3p transfection (Fig. 6A and C) but not with 
miR-19b or miR-24 (Figure S3) in EA.hy926 cells abolished TFPI up-regulation produced by 30 nM DHT as well 
as the anticoagulant activity, showing a relationship between testosterone, TFPI, and miR-27a/b-3p. In fact, when 
ECs transfected with anti-miR-27a/b-3p where treated with 15 nM DHT, we observed a significant increase of 
TFPI mRNA (Fig. 6B) and of the anticoagulant activity (Fig. 6C) further demonstrating the potential involvement 
of miR-27a/b-3p in the regulation of TFPI levels in ECs. The effect of miR-27a/b-3p mimics were also shown in 
HUVECs (Figure S4). Thus, the assessment of therapeutic alternatives with miRNAs may be of interest. This 
model suggests that in ECs high levels of miR-27a/b-3p might reduce the protective role of testosterone against 
cardiovascular disease14,15. This situation might be of particular relevance in men with low testosterone levels 
in relation with age or pathologies such as hypogonadism. Indeed, we hypothesized that miR-27a/b-3p may be 
upregulated in the plasma of men with low concentration of testosterone and TFPI13 in comparison with men 
with normal levels. Results showed no differences in miR-27a/b-3p expression that may be due to a substantial 
overlap of TFPI expression between the 2 groups (Fig. 7). Data from higher sample size will help to elucidate the 
role that miR-27a/b-3p may play in the testosterone mediated downregulation of TFPI in vivo, and thus whether 
Figure 2. miR-27a/b-3p directly target TFPI mRNA. (A) Schematic diagram of the luciferase reporter. 
Plasmids including TFPI WT 3′ UTR or TFPI mutant 3′ UTR in which the seven nucleotides forming the seed 
region of miR-27a/b-3p were deleted. (B) HTC-DK cells were transfected with either TFPI WT 3′ UTR or 
TFPI mutant 3′ UTR along with 100 nM miR-27a/b-3p precursor. A scrambled precursor was used as control. 
Luciferase activities were normalized to renilla activities. The 2−ΔCt method was followed to calculate the 
relative abundance of mRNA compared with endogenous control expression of β -actin (ACTB) (Ct = Threshold 
Cycle; Δ Ct = Ct sample gene - Ct endogenous control). All results are represented as mean ± SD from at least 
three experiments performed in triplicate (*p < 0.05; **p < 0.01).
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Figure 3. Ex vivo expression of TFPI mRNA and mature miRNAs. Levels of miR-27a-3p (A), miR-27b-3p 
(B), miR-19b (E) and miR-24 (F) were measured by qRT-PCR and correlated with TFPI mRNA expression in 74 
HUVEC samples obtained from umbilical cords. (C) Mean levels of miR-27a/b-3p in HUVECs. (D) correlation 
between miR-27a-3p and miR-27b-3p. The 2−ΔCt method was followed to calculate the relative abundance of 
miRNA compared with endogenous control expression of U6 (Ct = Threshold Cycle; Δ Ct = Ct sample gene - Ct 
endogenous control) (**p < 0.01).
www.nature.com/scientificreports/
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it could be a contributing factor to the risk of thrombosis associated with low testosterone levels14,15. In an attempt 
to further demonstrate the regulation of TFPI by miR-27a/b-3p through testosterone, we compared the levels of 
miR-27a/b-3p and TFPI mRNA in HUVECs in both genders and found no differences (Figure S5). This can be 
due because at delivery, even if testosterone levels are higher in boys than in girls these levels are 10 times lower 
than those found in adult individuals32. Thus, the regulatory role of testosterone in newborns may be probably 
negligible.
In conclusion, our results showed that miRNAs represent a novel mechanism by which TFPIα , a relevant hae-
mostatic molecule, is modulated in ECs. Further in vivo studies must be performed to reveal the real transcend-
ence of our results. We suggest that testosterone may be a hinge in miR-27a/b-3p-TFPIα regulation axis (Fig. 8). 
Given the high variability of miRNA expression levels among healthy population in different tissues, the patho-
physiological consequences of this regulation have yet to be established i.e., risk of cardiovascular disease33,34. In 
addition, the relevance of our experimental data should be further determined in the context of a potential use of 
miRNA inhibitors as anti-thrombotic drug.
Methods
In silico analysis of TFPI 3′UTR. To identify miRNA-binding sites located in human TFPI 3′ UTR 
(NM_006287) an in silico search using miRNA binding sites prediction programs was performed: miRSVR 
(http://www.microrna.org), TargetScan (http://www.targetscan.org), and miRWalk (http://www.umm.uni-hei-
delberg.de/apps/zmf/mirwalk/). MiRWalk covers five different algorithms (DIANA, miRDB, PITA, RNA22, and 
PICTAR).
Cell line and tissue samples. Endothelial cell line EA.hy926 was obtained from the American Type Culture 
Collection (Manassas, VA). ECs were maintained in phenol-red free DMEM supplemented with 2 mM glutamine, 
and 10% fetal bovine serum (Life Technologies, Madrid, Spain). Human colon cancer cell line HCT-116 defi-
cient for Dicer (HCT-DK) was a kind gift from Dr. Renato Baserga (Thomas Jefferson University, PA). HCT-DK 
were cultured in McCoy’s 5A (Sigma-Aldrich, Madrid, Spain) supplemented with 2 mM glutamine and 10% fetal 
bovine serum. Umbilical cord samples were obtained from healthy donors that gave informed consent (La Fe 
Hospital, Valencia, Spain) (n = 74). Studies with human HUVECs were approved by Local Ethics Committee 
from Hospital Universitario Morales Meseguer in Murcia and performed according to the declaration of Helsinki. 
Primary cultures of HUVECs were obtained by standard procedures. Briefly, HUVECs were obtained by colla-
genase digestion from umbilical cords from healthy donors, and were cultured at 37 °C in humidified air con-
taining 5% CO2. The selection of ECs was performed by filtration. HUVECs were grown to confluence in T-75 
flasks precoated with endothelial cell attachment factor (Sigma-Aldrich, Madrid, Spain), in medium M199 1X 
(+ ) Earle’s, 2mM L-glutamine, 25 mM HEPES, L-aminoacids (Life Technologies, Madrid, Spain), supplemented 
with 20% fetal bovine serum (Life Technologies, Madrid, Spain), 1% endothelial cell growth factor (ECGF) 
(Sigma-Aldrich, Madrid, Spain), 1 mM sodium pyruvate, 50 U/mL penicillin, and 50 μ g/mL streptomycin sul-
phate (Life Technologies, Madrid, Spain). Confluent EC monolayers were harvested from the culture flasks with 
0.25% trypsin/EDTA solution/0.02% PBS (Biochrom, Cambridge, UK). Cells to be used for total RNA isolation 
were stored at − 80 °C after adding 5 volumes of RNAlater (Life Technologies, Madrid, Spain). Although we had 
no direct confirmation that the isolated HUVECs were a pure endothelial culture, each culture was examined 
using a LEITZ DM-IRB inverted fluorescence research microscope (LEICA, Wetzlar, Germany) to ensure that 
the morphology was consistent with ECs. In all cases cells were cultured under conditions favoring EC growth 
Figure 4. miR-27a/b-3p regulate the anticoagulant activity of TFPIα in HUVECs. TFPIα anticoagulant 
activity was measured in the supernatant from HUVECs transfected with precursors or inhibitors of  
miR-27a/b-3p. All results are represented as mean ± SD from at least three experiments performed in triplicate 
(*p < 0.05; **p < 0.01).
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(medium supplemented with ECGF) and showed the same growth pattern: endothelial-like morphology like 
as cobblestone-shape area, spindle-shaped cell with cytoplasm distributed homogeneously, without presence of 
hyperplasia or hill-and-valley morphology, typical for vascular smooth muscle cells culture.
Figure 5. DHT regulates miR-27a/b-3p and TFPI expression. EA.hy926 cells were activated with 
physiological (30 nM) or low (15 nM) doses of DHT and TFPI mRNA (A), secreted TFPIα expression (B) and 
miR-27a/b-3p levels (C,D) were measured. (E) Levels of mRNA transcripts from enzymes implicated in the 
miRNA biogenesis: Drosha, Argonaute 2 (AGO2), Exportin 5 and Dicer were measured by qRT-PCR. The 2−ΔCt 
method was followed to calculate the relative abundance of miRNA or mRNA compared with endogenous 
control expression of U6 or ACTB (Ct = Threshold Cycle; Δ Ct = Ct sample gene - Ct endogenous control). All 
results are represented as mean ± SD from at least three experiments performed in triplicate (*p < 0.05).
www.nature.com/scientificreports/
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Cells were used within 2–3 passages for all experiments. All the cells were grown at 37 °C under 5% CO2 
atmosphere.
Endothelial cells transfections. EA.hy926 and HUVECs were seeded at 50,000/well and transfected 
with 100 nmol/L miRNA mimics (miR-27a/b-3p, miR-24, miR-19b or scrambled control -SCR-) from Life 
Technologies (Madrid, Spain) and anti-miRNA inhibitors (anti-miR-27a/b-3p or anti-SCR control) from Exiqon 
(Vedbaek, Denmark) using siPORT™ NeoFX™ (Life Technologies, Madrid, Spain) according to manufactur-
er’s instructions. After 48 h, cells and supernatants were collected for subsequent mRNA and protein analyses. 
Expression levels of miRNAs after transfection are shown in Supplemental Figure S6.
Total RNA isolation and qRT-PCR. Total RNA, including miRNAs, was isolated from EA.hy926 and 
HUVEC with RNAzol Reagent (Molecular Research Center Inc, Cincinnati, OH) according to manufac-
turer’s instructions. Isolation of miRNA from plasma was performed with NucleoSpin® miRNA plasma kit 
(Machery-Nagel, Düren, Germany). Reverse transcription (RT) reaction of total RNA (400 ng) was performed 
using SuperScript™ III First-Strand Synthesis System (Invitrogen, Madrid, Spain). MiRNA cDNA was syn-
thesized from total RNA purified from cells (200 ng) and from plasma (8 μ L of each sample) using individual 
miRNA-specific RT primers and the TaqMan® MicroRNA Reverse Transcription Kit (Life Technologies, Madrid, 
Spain). Each cDNA was amplified using the TaqMan® MicroRNA assays together with TaqMan® Universal PCR 
Figure 6. miR-27a/b-3p regulate DHT-dependent TFPI expression. EA.hy926 cells transfected with  
(A) miR-27a/b-3p precursors or (B) miR-27a/b-3p inhibitors were activated with 15 nM or 30 nM DHT. After 
48 h levels of TFPI mRNA were measured by qRT-PCR as well as TFPI anticoagulant activity (C). The 2−ΔCt 
method was followed to calculate the relative abundance TFPI mRNA compared with endogenous control 
expression of ACTB (Ct = Threshold Cycle; Δ Ct = Ct sample gene - Ct endogenous control). All results are 
represented as mean ± SD from at least three experiments performed in triplicate (*p < 0.05; **p < 0.01; 
***p < 0.001).
www.nature.com/scientificreports/
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Master Mix, No AmpErase® UNG (Life Technologies, Madrid, Spain). The 2−ΔCt method was followed to calcu-
late the relative abundance of miRNA and mRNA compared with endogenous control expression, U6 for cells 
miRNA and ACTB for mRNA. Plasma miRNA was normalized with geometric mean of miR-103-3p and miR-191 
(Ct = Threshold Cycle; Δ Ct = Ct sample gene-Ct endogenous control).
Western blotting and antibodies. Cell supernatants were collected from 24-well plates and BCA 
assays (ThermoFisher Scientific, Madrid, Spain) were performed to calculate protein concentration of samples. 
Protein concentration variability between samples was low (4.8–5.5 μ g/μ L for EAhy.926 and 1.3-1.6 μ g/μ L for 
HUVEC). Normalization in the western blot was based on the amount of protein loaded. For this purpose, 100 μg 
(EAhy.926) and 30 μ g (HUVEC) of total protein was separated by SDS-PAGE in reducing conditions by electro-
phoresis in 8% polyacrylamide gels. Gels were transferred onto PVDF membranes (Amersham Hybond P 0.45, 
GE Healthcare, Barcelona Spain) and blocked 1 hour in 5% w/v non-fat drymilk. Antibody against human TPFI 
(#ADG72, Sekisui Diagnostics, Rüsselsheim, Germany) was used 1:5,000 dilution and incubated overnight at 
4 °C. The secondary antibody labeled with peroxidase (GE Healthcare, Barcelona, Spain) was used 1:10,000. ECL 
Figure 7. Levels of miR-27a/b-3p in human plasma. (A) miR-27a and (B) miR-27b measured in plasma 
samples of 70 year-old patients with low TFPI (n = 37; 10.9 ± 2.3 ng/L) expression and normal TFPI (n = 41; 
12.3 ± 3 ng/L) expression13. The 2−ΔCt method was followed to calculate the relative abundance of miR-27a/b 
compared with control (geometric mean of miR-103-3p and miR-191) (Ct = Threshold Cycle; Δ Ct = Ct sample 
gene - Ct endogenous control). Lines indicate population median.
Figure 8. Schematic diagram of the TFPI regulatory mechanism by miRNAs. In the presence of normal 
levels of testosterone, TFPI expression is regulated in part by the presence of miR-27a/b in the cytosolic 
compartment. In physiological or pathological conditions where testosterone levels decrease, TFPI expression is 
downregulated due to a lower transcription of TFPI mRNA but also to a higher repression by miR-27a/b.
www.nature.com/scientificreports/
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Prime Detection Kit and ImageQuant LAS 4000 Imager (GE Healthcare, Barcelona, Spain) were used for sample 
detection. Densitometric analyses were performed with ImageJ software (http://rsb.info.nih.gov/ij/). Linearity 
between the amount of sample and densitometry was assessed (r2 = 0.95). Data were expressed as changes relative 
to cells transfected with SCR, taken as 100%.
Plasmid construction and deletion mutagenesis. PCR product (198 bp) containing a fragment 
of TFPI 3′ UTR (NM_006287) with miR-27a/b-3p binding site was cloned into pCR 2.1 vector (Life 
Technologies, Madrid, Spain) using the primers: (5′ GAGCTCCGTTATTTTTACCGTGTTTTG and 
5′ ACGCGTCGTTTGAGTGGTTTTCAG). SacI and MluI were used to digest positive clones (New 
England Biolabs, Ipswich, MA). The insert was subcloned into luciferase reporter plasmid pMIR-REPORT 
(Life Technologies, Madrid, Spain) previously digested with these enzymes. A deletion mutant of 
pMIR-REPORT-TFPI without miR-27a/b-3p seed region-binding site was generated using the primers S: 
5′ GAGCTCCGTTATTTTTACCGTGTTTTG and AS: 5′ ACGCGTCGTTTGAGTGGTTTTCAG with the 
QuikChange site-directed mutagenesis kit (Agilent Technologies, Santa Clara, CA). Insertion of TFPI 3′ UTR 
fragment and seed sequence deletion was confirmed by sequencing. PCR amplification was performed on plas-
mid DNA (Platinum Taq High Fidelity, Life Technologies, Madrid, Spain) and cleaned-up using ExoSAP-IT 
(Affymetrix, Santa Clara, CA). Sequences were performed using the BigDye Terminator Reaction Chemistry v3.1 
on Applied Biosystems 3130 XL DNA analyzers (Life Technologies, Madrid, Spain). Alignments and sequence 
analysis were performed using Seqman Pro program (Lasergene version 7.1, DNASTAR, Madison, WI).
Luciferase assay. HCT-DK cells were co-transfected with miR-27a/b-3p (both pMIR-REPORT plasmids 
− 500 ng/well-wild type or mutated for the miR-27a/b-3p seed site) or SCR control, and 50 ng/well of renilla lucif-
erase control plasmid (pRL-TK; Promega, Madison, WI) using Lipofectamine LTX (Life Technologies) according 
to the manufacturer’s instructions. After transfection (48 h), firefly and renilla luciferase activities were measured 
using the Dual-Glo Luciferase Reporter Assay (Promega, Madison, WI) in a Synergy 2 luminometer (Biotek, 
Winooski, VT).
TFPIα functional assay. The inhibitory activity of TFPIα was measured by functional chromogenic assay 
on supernatants from transfected cells (EAhy.926 and HUVECs), where TF-FVIIa dependent FXa generation 
was quantified using Actichrome® TFPI activity assay kit (Sekisui Diagnostics, Rüsselsheim, Germany) following 
manufacturer’s protocol. Briefly, 20 μ L of culture supernatant (adjusted by BCA method to optimal concentration 
depending on cell line) were added into the wells of a micro-test plate. Then, 20 μ L of FVIIa/TF complex were 
added and incubated at 37 °C for 30 min. After that, 20 μ L of human FX were added into each well and incubated 
for 15 min. After adding 20 μ L of EDTA, the reaction was initiated by adding 20 μ L of spectrozyme FXa substrate. 
Absorbance was read at 405 nm in a spectrophotometer for 10 min and Vmax was calculated.
Endothelial cells treatment. EA.hy926 and HUVEC cells pre-incubated for 48 h with 10% steroid-free 
FBS (charcoal/dextran-stripped serum from GE Hyclone, Logan, UT) were treated for 24 h with 15 nM or 30 nM 
(physiologic concentration) dihydrotestosterone (DHT) (Sigma-Aldrich, Madrid, Spain) or 0.1% ethanol (vehicle 
control).
Statistical analysis. Statistical analysis was performed with SPSS 21.0 (SPSS, Inc., Chicago, IL, USA) and 
GraphPad Prism 3.0 (GraphPad Software, Inc., La Jolla, CA, USA). For two groups comparisons, non-parametric 
test (U Mann–Whitney) was used. For multiple comparisons, one-way ANOVA on ranks with a post-hoc 
test (Bonferroni correction) were used. Association between continuous variables was analyzed by the 
Spearman’s rank correlation coefficient. Normal distribution of each variable was analyzed using one sample 
Kolmogorov-Smirnov test with Lilliefors significance correction. Results were expressed as mean ± SD. All tests 
were two-sided, and statistical significance was defined as a p-value < 0.05 (or smaller for corrected p-values in 
multiple comparisons).
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